Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ELIQUIS 2,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/ELIQUIS 2,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Approved

STANDARD

ELIQUIS 2,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

Bristol-Myers Squibb/Pfizer Eeig🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: May 26, 2023
Approval ID: e2af3ccd3e0769f7
Company: Bristol-Myers Squibb/Pfizer Eeig
Type: Standard

Approval Details

Approval Id: e2af3ccd3e0769f7
Drug Cima Aemps Name: ELIQUIS 2,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Register Number: 11691003IP
Holder Company Name: Bristol-Myers Squibb/Pfizer Eeig
Marketing Company Name: Melyfarma S.L.
Holder Company Detail Path: /organization/bristol-myers-squibb-pfizer-eeig
Authorization Date: 2023-05-26
Dosage Form: COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose: 2,5 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Bristol-Myers Squibb/Pfizer Eeig
Company Detail Path: /organization/bristol-myers-squibb-pfizer-eeig

Company Information

Pharmaceutical Company Name: BRISTOL-MYERS SQUIBB/PFIZER EEIG
Country Name: Ireland
City Name: dublin,country_ie
Address: Plaza 254 Blanchardstown Corporate Park 2

Active Ingredients

APIXABAN

2,5 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

May 26, 2023

Approval ID

e2af3ccd3e0769f7

Type

Standard

Back to CIMA-AEMPS Approvals